[18F]Fluorodeoxyglucose PET/Computed Tomography in Gastrointestinal Malignancies
- 1 October 2014
- journal article
- review article
- Published by Elsevier in PET Clinics
- Vol. 9 (4) , 421-441
Abstract
No abstract availableKeywords
This publication has 95 references indexed in Scilit:
- FDG–PET–CT reduces the interobserver variability in rectal tumor delineationRadiotherapy and Oncology, 2012
- Predictive value of metabolic 18FDG-PET response on outcomes in patients with locally advanced pancreatic carcinoma treated with definitive concurrent chemoradiotherapyBMC Gastroenterology, 2011
- Colorectal Cancer: CT Colonography and Colonoscopy for Detection—Systematic Review and Meta-AnalysisRadiology, 2011
- What is the most accurate whole-body imaging modality for assessment of local and distant recurrent disease in colorectal cancer? A meta-analysisEuropean Journal of Nuclear Medicine and Molecular Imaging, 2011
- Efficacy and safety of motesanib, an oral inhibitor of VEGF, PDGF, and Kit receptors, in patients with imatinib-resistant gastrointestinal stromal tumorsCancer Chemotherapy and Pharmacology, 2010
- Performance of imaging modalities in diagnosis of liver metastases from colorectal cancer: A systematic review and meta‐analysisJournal of Magnetic Resonance Imaging, 2009
- A Prospective Diagnostic Accuracy Study of 18F-Fluorodeoxyglucose Positron Emission Tomography/Computed Tomography, Multidetector Row Computed Tomography, and Magnetic Resonance Imaging in Primary Diagnosis and Staging of Pancreatic CancerAnnals of Surgery, 2009
- The role of PET/CT in detection of gastric cancer recurrenceBMC Cancer, 2009
- Impact of integrated positron emission tomography and computed tomography on staging and management of gallbladder cancer and cholangiocarcinomaJournal of Hepatology, 2006
- Efficacy and Safety of Imatinib Mesylate in Advanced Gastrointestinal Stromal TumorsNew England Journal of Medicine, 2002